Remission endpoints in ulcerative colitis: A systematic review
Summary of activity indices used for ulcerative colitis | Download Table
WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents
A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis
Metabolites | Free Full-Text | Mucosal Metabolomic Profiling and Pathway Analysis Reveal the Metabolic Signature of Ulcerative Colitis | HTML
The Efficacy of the Consumption of n-3 Polyunsaturated Fatty Acids for the Maintenance of Remission in Patients with Inflammatory Bowel Disease
The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis - Clinical Gastroenterology and Hepatology
Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods | Scientific Reports
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis Purpose
Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis - ScienceDirect
Comparison of the Ulcerative Colitis Disease Activity Index between the... | Download Table
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions - Clinical Gastroenterology and Hepatology
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild‐to‐moderate ulcerative colitis - Danese - 2019 - United European Gastroenterology Journal - Wiley Online Library
IBD Registry Web Tool User Guide
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study | Gut
UC-Disease Activity Index | Download Table
New approaches in the follow-up of patients suffering from inflammatory bowel diseases
Inflammatory Bowel Disease | Clinical Gate
Cells | Free Full-Text | A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study - Gastroenterology
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set - Clinical Gastroenterology and Hepatology
Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis | NEJM
Disease activity index (Schroeder and colleagues 14 ) | Download Table
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus - Vuitton - 2017 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Remission endpoints in ulcerative colitis: A systematic review
Diagnosis of acute severe colitis
